by Cary Miller | Mar 15, 2017 | PTAB Trial Basics
By Raffaella Faraoni, Ph.D. and Cary Miller, Ph.D. On March 3, 2017, in a final written decision in IPR2015-01838, the PTAB rejected an obviousness challenge brought by DuPont against a patent owned by Furanix Technologies B. V. directed to methods for preparing the...
by Matthew Johnson | Feb 1, 2017 | Final Written Decisions, Prior Art Issues
By Matt Johnson While touted by the Federal circuit as “a powerful tool for courts faced with the difficult task of avoiding subconscious reliance on hindsight,” objective indicia of non-obviousness have, to date at the PTAB, been little more than a secondary...
by Cary Miller | Jan 30, 2017 | 325(d) issues, Pharmaceutical, Real Party in Interest
By Kunyong Yang and Cary Miller, Ph.D. On January 19, 2017, the PTAB instituted inter partes review of U.S. Patent No. 8,822,438 (“the ’438 patent”) filed by Wockhardt Bio AG (“Wockhardt”) (IPR2016-01582). The ’438 patent is owned by Janssen Oncology, Inc....
by Jones Day's PTAB Team | Oct 28, 2016 | Pharmaceutical
By Wanli Tang, Ph.D. and J. Patrick Elsevier, Ph.D. On October 21, 2016, the PTAB issued two final written decisions in cases IPR2015-00990 and IPR2015-01093, invalidating claims 1-27, 31-40, 44-52 and 61-75 of U.S. Patent 7,056,886. These decisions mark the first...
by Jones Day's PTAB Team | Aug 29, 2016 | Other News
On August 23, 2016, the International Trade Commission (“ITC”) issued the public version of its Final Opinion in Certain Three-Dimensional Cinema Systems and Components Thereof, Inv. No. 337-TA-939, clarifying the effect of Inter Partes Review (IPR)...